Eventide Asset Management HTFL Position
Active5-Fund ConvergenceEventide Asset Management increased their position in Heartflow, Inc. (HTFL) in Q4 2025, holding $14.8M worth of shares across 505,989 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
HTFL is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Heartflow, Inc.
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company's platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. The company was founded in 2007 and is headquartered in Mountain View, California.
Full company profile →Short Interest
6.6%
4.2 days to cover
Eventide Asset Management HTFL Position History
Frequently Asked Questions
Does Eventide Asset Management own HTFL?
Yes. As of Q4 2025, Eventide Asset Management holds 505,989 shares of Heartflow, Inc. (HTFL) valued at $14.8M. This data comes from their SEC 13F filing.
How many hedge funds own HTFL?
5 specialist biotech hedge funds currently hold HTFL, including RTW Investments, Rock Springs Capital, Perceptive Advisors and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy HTFL?
Eventide Asset Management's position in HTFL was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's HTFL position increasing or decreasing?
Eventide Asset Management increased their HTFL position in the most recent quarter, adding 421,999 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HTFLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →